Literature DB >> 28017540

Transcription Factor EB Expression in Early Breast Cancer Relates to Lysosomal/Autophagosomal Markers and Prognosis.

Alexandra Giatromanolaki1, Efthimios Sivridis1, Dimitra Kalamida2, Michael I Koukourakis3.   

Abstract

BACKGROUND: Disrupting the autophagic balance to trigger autophagic death may open new strategies for cancer therapy. Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and may play a role in cancer biology and clinical behavior.
METHODS: The expression of TFEB and the lysosomal cancer cell content (expression of lysosomal associated membrane protein 2a [LAMP2a] and cathepsin D) was studied in a series of 100 T1-stage breast carcinomas. Expression patterns were correlated with autophagy/hypoxia-related proteins, angiogenesis, and clinical outcome. The effect of hypoxic/acidic conditions on TFEB kinetics was studied in the MCF-7 cancer cell line.
RESULTS: Overexpression of TFEB in cancer cell cytoplasm and the perinuclear/nuclear area was noted in 23 (23%) of 100 cases. High LAMP2a and cathepsin D expression was noted in 30 (30%) of 100 and 28 (28%) of 100 cases, respectively. TFEB expression was directly linked with LAMP2a (P < .0001, r = 0.53), cathepsin D (P = .0002, r = 0.36), light chain 3A (LC3A) (P = .02, r = 0.22), and hypoxia-inducible factor 2-alpha (HIF-2α) (P = .01, r = 0.25) expression and inversely with progesterone receptor (P = .01, r = 0.22). High vascular density was directly linked with LAMP2a (P = .05, r = 0.18) and cathepsin D (P = .005, r = 0.28). In Kaplan-Meier survival analysis, TFEB and cathepsin D expression were related to an ominous prognosis (P = .001 and P = .03, respectively). In multivariate analysis, TFEB expression sustained its independent prognostic significance (P = .05, hazard ratio 2.1). In in vitro experiments, acidity triggered overexpression of TFEB and nuclear translocation.
CONCLUSION: Intense TFEB expression and lysosomal biogenesis, evident in one fourth of early breast carcinomas, define poor prognosis. Tumor acidity is among the microenvironmental conditions that trigger TFEB overactivity. TFEB is a sound target for the development of lysosomal targeting therapies.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acidity; Breast cancer; Cathepsin D; LAMP2a; TFEB

Mesh:

Substances:

Year:  2016        PMID: 28017540     DOI: 10.1016/j.clbc.2016.11.006

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  11 in total

Review 1.  Past, present, and future perspectives of transcription factor EB (TFEB): mechanisms of regulation and association with disease.

Authors:  Anderson Tan; Renuka Prasad; Chaerin Lee; Eek-Hoon Jho
Journal:  Cell Death Differ       Date:  2022-06-23       Impact factor: 12.067

Review 2.  Dissecting pharmacological effects of chloroquine in cancer treatment: interference with inflammatory signaling pathways.

Authors:  Lokman Varisli; Osman Cen; Spiros Vlahopoulos
Journal:  Immunology       Date:  2019-12-22       Impact factor: 7.397

3.  Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression.

Authors:  Ruibo Wang; Yantong Liu; Li Liu; Mei Chen; Xiuxuan Wang; Jingyun Yang; Yanqiu Gong; Bi-Sen Ding; Yuquan Wei; Xiawei Wei
Journal:  EBioMedicine       Date:  2019-01-30       Impact factor: 8.143

4.  Prognostic role of high cathepsin D expression in breast cancer: a systematic review and meta-analysis.

Authors:  Junho Kang; Yeuni Yu; Seongdo Jeong; Hansong Lee; Hye Jin Heo; Jeong Jun Park; Hee Sam Na; Dai Sik Ko; Yun Hak Kim
Journal:  Ther Adv Med Oncol       Date:  2020-06-08       Impact factor: 8.168

5.  TFEB Promotes Prostate Cancer Progression via Regulating ABCA2-Dependent Lysosomal Biogenesis.

Authors:  Xuejin Zhu; Yangjia Zhuo; Shulin Wu; Yanfei Chen; Jianheng Ye; Yulin Deng; Yuanfa Feng; Ren Liu; Shanghua Cai; Zhihao Zou; Bin Wang; Chin-Lee Wu; Guohua Zeng; Weide Zhong
Journal:  Front Oncol       Date:  2021-03-01       Impact factor: 6.244

Review 6.  Chaperone Mediated Autophagy Substrates and Components in Cancer.

Authors:  Javiera Rios; Alvaro Sequeida; Amelina Albornoz; Mauricio Budini
Journal:  Front Oncol       Date:  2021-02-12       Impact factor: 6.244

7.  TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study.

Authors:  Serena Bertozzi; Ambrogio P Londero; Luigi Viola; Maria Orsaria; Michela Bulfoni; Stefania Marzinotto; Bruna Corradetti; Umberto Baccarani; Daniela Cesselli; Carla Cedolini; Laura Mariuzzi
Journal:  BMC Cancer       Date:  2021-10-18       Impact factor: 4.430

8.  Expanding the phenotype of E318K (c.952G > A) MITF germline mutation carriers: case series and review of the literature.

Authors:  Leandro Jonata Carvalho Oliveira; Aline Bobato Lara Gongora; Fabiola Ambrosio Silveira Lima; Felipe Sales Nogueira Amorim Canedo; Carla Vanessa Quirino; Janina Pontes Pisani; Maria Isabel Achatz; Benedito Mauro Rossi
Journal:  Hered Cancer Clin Pract       Date:  2021-07-21       Impact factor: 2.857

Review 9.  Multifaceted activities of transcription factor EB in cancer onset and progression.

Authors:  Elena Astanina; Federico Bussolino; Gabriella Doronzo
Journal:  Mol Oncol       Date:  2020-12-23       Impact factor: 7.449

10.  TFEB Regulates ATP7B Expression to Promote Platinum Chemoresistance in Human Ovarian Cancer Cells.

Authors:  Raffaella Petruzzelli; Marta Mariniello; Rossella De Cegli; Federico Catalano; Floriana Guida; Elia Di Schiavi; Roman S Polishchuk
Journal:  Cells       Date:  2022-01-10       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.